NRx Pharmaceuticals announced that it intends to offer to sell shares of its common stock in an underwritten public offering. All of the shares of common stock are to be sold by the company. EF Hutton is acting as the sole book-running manager for the offering.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NRXP:
- NRx Pharmaceuticals develops new proprietary formulation of HTX-100
- NRx Pharmaceuticals achieves data-lock of Phase 2b/3 trial of NRX-101
- NRX Pharmaceuticals trading halted, news pending
- NRx Pharmaceuticals (Nasdaq:NRXP) Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Navigating the Minefield: Nrx Pharmaceuticals’ Tightrope Walk Between Safety Regulations and Operational Hazards